Cadmium complexes and cocrystals of indium complexes of benzothiazole derivatives and anticancer activities of the cadmium complexes

A Novel Dinuclear Complex-PLC Composite Material as Fluorescent Switch in Treatment on Osteoarthritis

In this study, we synthesized a novel Co(II)-containing coordination compound (CP) [Co2(MMBA)2(HPT)2(H2O)2]·2H2O (1) through a solvothermal reaction of Co(NO3)6·6H2O with 3-(pyridin-2-yl)-1 H-1,2,4-triazole (HPT) and 2-(4-methylbenzoyl)benzoic acid (HMMBA). Fluorescence spectroscopy confirmed that this compound exhibited superior blue fluorescence properties compared to the original ligands. Further, aspirin (ASA) was loaded onto this CP via physical adsorption to create CP-ASA. Interestingly, the fluorescence properties of the CP decreased with the loading of the drug but were restored upon drug release. Leveraging the unique optical properties and biocompatibility of Polymer Liquid Crystal (PLC), we further encapsulated CP-ASA, forming the CP-PLC@ASA composite. The target product was confirmed through various characterization techniques including Elemental Analysis (EA), Fourier-Transform Infrared Spectroscopy (FT-IR), Powder X-Ray Diffraction (PXRD), and Thermogravimetric Analysis (TGA). Moreover, the biological activity of this composite was evaluated in vitro for osteoarthritis, and its potential mechanisms were explored.

Novel {Cu4} and {Cu4Cd6} clusters derived from flexible aminoalcohols: synthesis, characterization, crystal structures, and evaluation of anticancer properties

Two new copper clusters, {Cu₄} and {Cu₄Cd₆}, with polydentate aminoalcohol ligands, diethanol propanolamine (H₃L¹) and bis-tris{2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol} (H₆L²), have been synthesized under mild conditions and characterized thoroughly by single-crystal X-ray diffraction (XRD), infrared spectroscopy, elemental analysis, powder XRD, magnetic and DFT studies, and absorption and fluorescence spectroscopy. The cluster {Cu₄} exhibits a rare tetranuclear copper cubane core whereas {Cu₄Cd₆} forms an unusual heterometallic cage owing to the introduction of the second metal Cd into the ligand. A hexapodal ligand (H₆L²) with N and O donor atoms was chosen deliberately for the construction of a high-nuclearity cluster, i.e., {Cu₄Cd₆}. Interestingly, both the clusters displayed significant cytotoxicity towards human cervical (HeLa) and lung (A549) cancer cells as evident from the shallow IC₅₀ values [15.6 ± 0.8 μM (HeLa), 18.5 ± 1.9 μM (A549) for {Cu₄}, and 11.1 ± 1.5 μM (HeLa), 10.2 ± 1.3 μM (A549) for {Cu₄Cd₆}] obtained after a 24 h incubation. However, moderate toxicity was observed toward immortalized lung epithelial normal cells (HPL1D) with IC₅₀ values of 32.4 ± 1.2 μM for {Cu₄} and 27.6 ± 1.7 μM for {Cu₄Cd₆}. A cellular apoptotic study using HeLa cells revealed that the {Cu₄} cluster triggered apoptosis at both the early and late phases while the {Cu₄Cd₆} cluster facilitate apoptosis mainly at the late apoptotic stage. A standard 2',7'-dichlorodihydrofluorescein-diacetate (DCFH-DA) test affirms that both the clusters enhanced ROS production inside the cancer cells, responsible for promoting cell apoptosis. The decanuclear {Cu₄Cd₆} clusters demonstrated better anticancer activity compared to the tetranuclear {Cu₄} clusters, indicating the role of high nuclearity and additional Cd metal in the enhanced intracellular production of ROS.

Synthesis, DFT Calculations, Antiproliferative, Bactericidal Activity and Molecular Docking of Novel Mixed-Ligand Salen/8-Hydroxyquinoline Metal Complexes

Despite the common use of salens and hydroxyquinolines as therapeutic and bioactive agents, their metal complexes are still under development. Here, we report the synthesis of novel mixed-ligand metal complexes (MSQ) comprising salen (S), derived from (2,2′-{1,2-ethanediylbis[nitrilo(E) methylylidene]}diphenol, and 8-hydroxyquinoline (Q) with Co(II), Ni(II), Cd(II), Al(III), and La(III). The structures and properties of these MSQ metal complexes were investigated using molar conductivity, melting point, FTIR, ¹H NMR, ¹³C NMR, UV–VIS, mass spectra, and thermal analysis. Quantum calculation, analytical, and experimental measurements seem to suggest the proposed structure of the compounds and its uncommon monobasic tridentate binding mode of salen via phenolic oxygen, azomethine group, and the NH group. The general molecular formula of MSQ metal complexes is [M(S)(Q)(H₂O)] for M (II) = Co, Ni, and Cd or [M(S)(Q)(Cl)] and [M(S)(Q)(H₂O)]Cl for M(III) = La and Al, respectively. Importantly, all prepared metal complexes were evaluated for their antimicrobial and anticancer activities. The metal complexes exhibited high cytotoxic potency against human breast cancer (MDA-MB231) and liver cancer (Hep-G2) cell lines. Among all MSQ metal complexes, CoSQ and LaSQ produced IC₅₀ values (1.49 and 1.95 µM, respectively) that were comparable to that of cisplatin (1.55 µM) against Hep-G2 cells, whereas CdSQ and LaSQ had best potency against MDA-MB231 with IC₅₀ values of 1.95 and 1.43 µM, respectively. Furthermore, the metal complexes exhibited significant antimicrobial activities against a wide spectrum of both Gram-positive and -negative bacterial and fungal strains. The antibacterial and antifungal efficacies for the MSQ metal complexes, the free S and Q ligands, and the standard drugs gentamycin and ketoconazole decreased in the order AlSQ > LaSQ > CdSQ > gentamycin > NiSQ > CoSQ > Q > S for antibacterial activity, and for antifungal activity followed the trend of LaSQ > AlSQ > CdSQ > ketoconazole > NiSQ > CoSQ > Q > S. Molecular docking studies were performed to investigate the binding of the synthesized compounds with breast cancer oxidoreductase (PDB ID: 3HB5). According to the data obtained, the most probable coordination geometry is octahedral for all the metal complexes. The molecular and electronic structures of the metal complexes were optimized theoretically, and their quantum chemical parameters were calculated. PXRD results for the Cd(II) and La(III) metal complexes indicated that they were crystalline in nature.

A novel binuclear hydrazone-based Cd(II) complex is a strong pro-apoptotic inducer with significant activity against 2D and 3D pancreatic cancer stem cells

A novel binuclear Cd complex (1) with hydrazone-based ligand was prepared and characterized by spectroscopy and single crystal X-ray diffraction techniques. Complex 1 reveals a strong pro-apoptotic activity in both human, mammary adenocarcinoma cells (MCF-7) and pancreatic AsPC-1 cancer stem cells (CSCs). While apoptosis undergoes mostly caspase-independent, 1 stimulates the activation of intrinsic pathway with noteworthy down regulation of caspase-8 activity in respect to non-treated controls. Distribution of cells over mitotic division indicates that 1 caused DNA damage in both cell lines, which is confirmed in DNA interaction studies. Compared to 1, cisplatin (CDDP) does not achieve cell death in 2D cultured AsPC-1 cells, while induces different pattern of cell cycle changes and caspase activation in 2D cultured MCF-7 cells, implying that these two compounds do not share similar mechanism of action. Additionally, 1 acts as a powerful inducer of mitochondrial superoxide production with dissipated trans-membrane potential in the majority of the treated cells already after 6 h of incubation. On 3D tumors, 1 displays a superior activity against CSC model, and at 100 μM induces disintegration of spheroids within 2 days of incubation. Fluorescence spectroscopy, along with molecular docking show that compound 1 binds to the minor groove of DNA. Compound 1 binds to the human serum albumin (HSA) showing that the HSA can effectively transport and store 1 in the human body. Thus, our current study strongly supports further investigations on antitumor activity of 1 as a drug candidate for the treatment of highly resistant pancreatic cancer.

Synthesis, characterization, and evaluation of Cd[L-proline]2, a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells

Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression through their effects on the compact chromatin structure. In clinical studies, several classes of histone deacetylase inhibitors (HDACi) have demonstrated potent anticancer activities with metal complexes. Hence, we synthesized cadmium-proline complexes using both the D- and L-isomers of proline and evaluated their biological activities by observing the efficiency of their inhibition of HDAC activity, ability to reduce the expression of HDAC isoforms in A549 cells and effect on apoptosis. The synthesized compounds were characterized by UV, IR, NMR spectroscopy and elemental analysis. In-vitro cell toxicity was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, and the 50% inhibitory concentration (IC₅₀; 2 μM) was obtained at 12 h. The morphological study at nuclear levels was performed by acridine orange/ethidium bromide (AO/EB) and Hoechst staining, and the results showed an association with cell cycle arrest at the G2/M phase. Both cadmium-proline complexes intensely inhibited HDAC activity at 2 μM concentration. Interestingly, Cd[L-proline]₂ was found to be a potent inhibitor for all HDAC isoforms, whereas Cd[D-proline]₂ inhibited only HDAC1 and 2. HDACi are novel chemotherapeutic drugs that induce hyperacetylation of histones H3 and H4, counteracting the aberrant repression of genes, such as insulin-like growth factor-binding protein 3 (IGFBP-3), p53, and p21. ERK/MAPK signaling pathway resulted in the downregulation of the expression of matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9), contributing to the inhibition of metastasis in A549 cells. Apoptosis induction was accompanied by the activation of death receptors and their ligands which recruit initiator caspase 8, decrease in mitochondrial membrane potential (ΔΨm), as well as increased Bax/Bcl₂ ratio, followed by activation of caspases 9 and 3. Our finding suggests that Cd[L-proline]₂ complex accelerates epigenetic rearrangement by HDAC inhibition, which may be the key mechanism for its anticancer activity.

Recent advances in the chemistry and biology of benzothiazoles

Benzothiazole is a privileged heterocyclic scaffold having a benzene ring fused with a five-membered thiazole ring. This moiety has attracted considerable attention because of its wide range of pharmacological activities such as antitubercular, antimicrobial, antimalarial, anticonvulsant, anthelmintic, analgesic, anti-inflammatory, antidiabetic, antitumor activity, etc. In the last few years, some novel benzothiazoles have been developed with varied biological activities. To access this scaffold in high yield and to introduce diversity, a variety of new synthetic methods have been invented. In this review, we highlight the development of novel benzothiazoles for various biological activities along with the best synthetic protocols for their synthesis.

Heteronuclear gold(I)-silver(I) sulfanylcarboxylates: Synthesis, structure and cytotoxic activity against cancer cell lines

Heteronuclear complexes of the type [AgAu(PPh3)2(xspa)] [H2xspa=3-(aryl)-2-sulfanylpropenoic acids; (x=3-phenyl-; 3-(2-chlorophenyl)-; 3-(o-methoxyphenyl)-; 3-(p-methoxyphenyl)-; 3-(p-hydroxyphenyl)-; 3-(2-furyl)-; 3-(2-thienyl)-; spa=2-sulfanylpropenoate)] were prepared by reacting the appropriate [Au(PPh3)(Hxspa)] precursor with Ag(PPh3)NO3. The compounds were characterized by spectroscopic methods, (IR; (1)H, (13)C and (31)P NMR) and mass spectrometry and the structures of the phenyl and p-methoxyphenyl derivatives were determined by X-ray diffraction. The in vitro antitumor activity against the HeLa-229, A2780 and A2780cis cell lines was determined and compared with that of cisplatin and the equivalent homonuclear gold(I) complexes.